Form 4: Arcutis Director Exercises Options, Sells Shares

Arcutis Biotherapeutics Director Keith R. Leonard exercised stock options and subsequently sold a portion of the acquired common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Keith R. Leonard, a Director of Arcutis Biotherapeutics, Inc. (ARQT), engaged in transactions on March 2, 2026, under a Rule 10b5-1 trading plan adopted on November 18, 2025.
• Exercised options to acquire 27,052 shares of common stock at an exercise price of $8.63 per share.
• Exercised options to acquire an additional 12,220 shares of common stock at an exercise price of $7.51 per share.
• Sold 39,272 shares of common stock at a weighted average price of $25.392 per share, with individual sales ranging from $25.05 to $26.039.
• Following these transactions, Leonard directly owns 22,123 shares and indirectly owns 1,750 shares through the Leonard Family Trust.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While there is a sale of shares, it's part of a pre-arranged plan and follows the exercise of options at significantly lower prices, indicating a realization of value from prior compensation.

Positives

• Exercising options indicates a belief in the value of the underlying stock at the time the options were granted, and allows the director to realize value from vested equity.
• The exercise prices of $8.63 and $7.51 are significantly lower than the sale price of $25.392, indicating a substantial profit on the exercised shares.

Negatives

• The sale of 39,272 shares reduces the director's direct ownership in the company, which could be interpreted as a reduction in direct exposure to the company's future performance.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under a Rule 10b5-1 plan, are common in the biotherapeutics industry as executives manage their equity compensation and personal financial planning. While sales can sometimes be viewed negatively, a pre-arranged plan mitigates concerns about opportunistic timing.

Related Party Transactions

• Keith R. Leonard indirectly holds 1,750 shares through the Leonard Family Trust dated August 28, 1996, of which he is a trustee. He disclaims beneficial ownership except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders: The sale of shares by a director could be perceived as a slight negative, but the execution under a 10b5-1 plan suggests a planned financial move rather than a lack of confidence in the company. The overall impact is likely minimal given the context.

Next Steps

• The 10b5-1 trading plan has an end date of February 16, 2027, suggesting potential future transactions under this plan.

Key Dates

Recommendation

The transactions are routine insider activity under a pre-arranged 10b5-1 plan, involving both option exercises and subsequent sales. This type of filing typically does not provide new fundamental information about the company's operations or future prospects that would warrant a change in investment thesis. The director is realizing value from vested equity, which is a common practice.

Keywords

Arcutis Biotherapeutics, ARQT, Keith R. Leonard, Insider Trading, Form 4, Stock Options, Share Sale, 10b5-1 Plan, Director Transactions, Biotherapeutics